A guide to early FX rates - and the usual caveats about thin liquidity apply!
Most Popular
Sponsored
REGN's 19% revenue growth & 15% adjusted EPS growth at 16.5 P/E is a buy signal despite Eylea's dip.
AMGN beats Q1 estimates with 5.8% revenue growth & 8% EPS beat. New drugs drive gains, but legacy products face headwinds.
AXSM jumps 22.9% on Alzheimer's drug approval; analysts raise price targets to $255.
PWR beats revenue/EPS estimates, lifts guidance. Strong backlog growth signals robust demand.
Heathrow's £49B runway faces airline pushback over costs; China fund eyes exit amid risk.
ZTS's 9.1% revenue growth & 16.2x P/E show promise; IBM & CSGP face headwinds with soft growth & high P/E.
Amtrak secures $33B infrastructure funds, cutting costs on Baltimore tunnel project to $5B.
Sponsored
Must Read
